Single-Agent Doxorubicin Dosing for Recurrent Myxofibrosarcoma
For an adult with recurrent myxofibrosarcoma and normal organ function, use doxorubicin 75 mg/m² IV every 3 weeks as single-agent first-line chemotherapy. This represents the standard anthracycline-based approach for advanced soft tissue sarcomas, including myxofibrosarcoma 1, 2, 1, 2, 3.
Dosing Rationale
The 75 mg/m² dose every 3 weeks is the established standard based on the landmark EORTC trial that compared single-agent doxorubicin at this dose against combination regimens 4. This study demonstrated that single-agent doxorubicin 75 mg/m² achieved a 23.3% response rate with median overall survival of 52 weeks, and importantly showed no survival advantage for more toxic combination regimens. Multiple ESMO guidelines consistently cite anthracyclines as first-line standard treatment for advanced soft tissue sarcomas 1, 2, 1, 2, 5, 3.
Alternative Dosing Considerations
While 75 mg/m² every 3 weeks is standard, you may encounter these alternatives in specific clinical contexts:
- 50 mg/m² every 3 weeks: Used in combination regimens (doxorubicin + ifosfamide) 6, but when using single-agent therapy, the higher 75 mg/m² dose is preferred for optimal efficacy
- 60 mg/m² every 3 weeks: Common in breast cancer regimens 7, but not the established standard for sarcomas
- High-dose protocols (120 mg/m²): Explored in research settings but showed unacceptable toxicity without clear survival benefit and are not recommended for routine practice 8
Critical Monitoring Requirements
Cardiac function monitoring is mandatory given doxorubicin's dose-dependent cardiotoxicity:
- Baseline cardiac assessment (echocardiogram or MUGA scan)
- Serial monitoring during treatment, particularly as cumulative doses approach 450-550 mg/m²
- Female patients and those with higher ECOG performance status have increased cardiotoxicity risk 9
- Consider discontinuation or dose reduction if ejection fraction drops significantly
Treatment Duration
Continue doxorubicin until:
- Maximum cumulative dose reached (typically 450-550 mg/m² to minimize cardiac risk)
- Disease progression
- Unacceptable toxicity
- Patient achieves maximum response
When to Consider Combination Therapy Instead
The 2022 SELNET guidelines 10 and 2021 ESMO-EURACAN guidelines 3 indicate that combination therapy with doxorubicin plus ifosfamide may be preferred when:
- Tumor shrinkage is critically needed for symptom palliation or potential surgical conversion
- Patient has excellent performance status (ECOG 0-1)
- Histology is particularly ifosfamide-sensitive (though myxofibrosarcoma shows moderate sensitivity)
However, for myxofibrosarcoma specifically, single-agent doxorubicin remains appropriate first-line therapy as there is no formal demonstration that combination chemotherapy improves overall survival compared to sequential single agents 1, 2, 1, 2, 3.
Common Pitfall to Avoid
Do not automatically escalate to combination therapy without clear indication. The meta-analysis by the Sarcoma Disease Site Group 11 demonstrated that doxorubicin-based combinations produce only marginal increases in response rates at the expense of significantly increased toxicity, with no improvement in overall survival. Reserve combination therapy for situations where rapid tumor response provides meaningful clinical benefit.